Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
06:59am, Friday, 19'th Sep 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025.
Dividend Harvesting Portfolio Week 237: $23,700 Allocated, $2,573.68 In Projected Dividends
08:45am, Thursday, 18'th Sep 2025
The Dividend Harvesting Portfolio reached all-time highs, up 34.27% on invested capital and producing $2,573.68 in forward annualized dividend income. Recent additions include NNN REIT, Bristol Myers,
J&J's experimental psoriasis drug shows promise against Bristol's treatment
08:27am, Wednesday, 17'th Sep 2025
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
Bristol Myers Squibb Announces Dividend
06:59am, Wednesday, 17'th Sep 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers to sell 60% stake in China joint venture
12:04am, Wednesday, 17'th Sep 2025
U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.
10 Quality High Yield In Rose's Income Garden Portfolio: 5 Winners To Buy
10:46am, Tuesday, 16'th Sep 2025
Highlighting 10 S&P-rated companies with 4-7% yields, focusing on dividend growth, credit quality, and undervaluation. Pfizer, Alexandria RE, NNN REIT, AES Corp, and Bristol Myers are identified as un
Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
06:59am, Tuesday, 16'th Sep 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum.
5 Stocks Yielding 5% and More to Buy and Hold for the Next 5 Years
09:43am, Sunday, 14'th Sep 2025
Dividend stocks are a favorite among investors for good reason. They provide a steady stream of passive income and offer a promising avenue for total return.
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
03:12pm, Friday, 12'th Sep 2025
Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 d
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
10:11am, Friday, 12'th Sep 2025
Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 12'th Sep 2025
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
10:56am, Thursday, 11'th Sep 2025
Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know
06:46pm, Tuesday, 09'th Sep 2025
In the latest trading session, Bristol Myers Squibb (BMY) closed at $47.23, marking a +1.09% move from the previous day.
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
02:01pm, Monday, 08'th Sep 2025
BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCL
Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
12:15pm, Monday, 08'th Sep 2025
Bristol-Myers Squibb Company (NYSE:BMY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Boerner - CEO & Chairman Adam Lenkowsky
